Stock Analysis on Net

Pfizer Inc. (NYSE:PFE)

$24.99

Analysis of Solvency Ratios
Quarterly Data

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Solvency Ratios (Summary)

Pfizer Inc., solvency ratios (quarterly data)

Microsoft Excel
Mar 30, 2025 Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022 Dec 31, 2021 Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020
Debt Ratios
Debt to equity
Debt to capital
Debt to assets
Financial leverage

Based on: 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29).


The analysis of the financial leverage and debt-related ratios over the reported quarters highlights several key trends.

Debt to equity ratio
The debt to equity ratio exhibits an overall declining trend from March 2020 through the end of 2022, moving from 0.8 down to a low of 0.36 by the second quarter of 2023. This decline suggests a reduction in the company's reliance on debt financing relative to equity during this period. Starting mid-2023, the ratio increases notably, reaching peaks near 0.81 by the fourth quarter of 2023 before slightly dropping and stabilizing around 0.69 by the first quarter of 2025. This indicates a renewed increase in leverage but still below some of the initial levels noted in 2020.
Debt to capital ratio
This ratio also follows a similar pattern as debt to equity, declining from 0.45 in March 2020 to a lower point near 0.26 in early 2023. After this trough, it rises back to about 0.45 by the end of 2023 before gradually decreasing again to approximately 0.41 by the first quarter of 2025. The pattern suggests cautious management of overall capital structure with temporary increases in the debt component.
Debt to assets ratio
The debt to assets ratio decreases steadily from 0.31 in March 2020 to around 0.18 in early 2023, reflecting improved asset coverage or lower debt levels. However, similar to the other debt ratios, this ratio increases sharply in mid-2023 to roughly 0.3, before moderately declining and stabilizing near 0.3 through early 2025. This trend signals fluctuations in asset financing strategy or asset base adjustments affecting leverage.
Financial leverage ratio
Financial leverage shows a moderate downward trend from 2.56 in early 2020 to a low of 1.94 in the first quarter of 2023, indicating deleveraging or increased equity relative to total assets. Following this low, the leverage ratio rebounds to 2.54 by the end of 2023 and then experiences slight declines but remains elevated above 2.3 into 2025. This pattern suggests a strategic shift towards increased financial leverage after a period of reduction.

Overall, the data reveals a phase of deleveraging and improving capital structure from 2020 until early 2023, with consistent reductions in debt-related ratios. From mid-2023 onward, there is a noticeable reversal with a rise in leverage and debt ratios, potentially indicating new financing activities or changes in asset composition. Despite these fluctuations, the leverage measures stay within moderate ranges, reflecting balanced financial management practices.


Debt Ratios


Debt to Equity

Pfizer Inc., debt to equity calculation (quarterly data)

Microsoft Excel
Mar 30, 2025 Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022 Dec 31, 2021 Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020
Selected Financial Data (US$ in millions)
Short-term borrowings, including current portion of long-term debt
Long-term debt, excluding current portion
Total debt
 
Total Pfizer Inc. shareholders’ equity
Solvency Ratio
Debt to equity1
Benchmarks
Debt to Equity, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29).

1 Q1 2025 Calculation
Debt to equity = Total debt ÷ Total Pfizer Inc. shareholders’ equity
= ÷ =

2 Click competitor name to see calculations.


The analysis of the financial data reveals distinct trends in the company's total debt, shareholders’ equity, and debt-to-equity ratio over the observed quarterly periods.

Total Debt
The total debt exhibits notable fluctuations across the quarters. Starting at 52,288 million USD in the first quarter of 2020, it peaked at 63,613 million USD in the second quarter of 2020 before decreasing sharply to 39,836 million USD by the end of 2020. For most of 2021 and early 2022, the debt remained relatively stable around 35,000 to 40,000 million USD. However, a significant increase occurred in the second quarter of 2023, reaching 65,341 million USD, maintaining a high level through subsequent quarters, with a slight downward trend toward the first quarter of 2025, ending at 62,109 million USD.
Total Shareholders’ Equity
The shareholders’ equity consistently increased from 65,026 million USD in the first quarter of 2020 to a peak of 100,970 million USD in the first quarter of 2023. After this peak, equity experienced a slight decline and oscillated in the 87,000 to 99,000 million USD range through to early 2025. This indicates a generally positive growth trajectory in equity, with minor contractions in the later periods.
Debt-to-Equity Ratio
The debt-to-equity ratio initially increased from 0.80 in the first quarter of 2020 to a peak of approximately 0.99 by the second quarter of 2020, mirroring the debt increase and relatively stable equity at that time. Subsequently, the ratio declined sharply to approximately 0.37 by the last quarter of 2022, reflecting both the reduction in debt and increases in equity. Starting from early 2023, the ratio rose again, reaching around 0.81 in the third quarter of 2023 and remaining relatively elevated, fluctuating between 0.69 and 0.81 thereafter through to the first quarter of 2025.

Overall, the data suggest a period of rising leverage in early 2020, followed by deleveraging through to late 2022, and renewed increase in leverage from early 2023 onwards. Concurrently, the shareholders’ equity increased substantially until early 2023, before stabilizing and experiencing minor decreases. These trends reflect dynamic financial management with changes in capital structure, impacting the balance between debt and equity financing over the reported periods.


Debt to Capital

Pfizer Inc., debt to capital calculation (quarterly data)

Microsoft Excel
Mar 30, 2025 Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022 Dec 31, 2021 Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020
Selected Financial Data (US$ in millions)
Short-term borrowings, including current portion of long-term debt
Long-term debt, excluding current portion
Total debt
Total Pfizer Inc. shareholders’ equity
Total capital
Solvency Ratio
Debt to capital1
Benchmarks
Debt to Capital, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29).

1 Q1 2025 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =

2 Click competitor name to see calculations.


The analysis of the financial data over the reported periods reveals distinct trends in debt management and capital structure.

Total Debt
Total debt exhibited significant fluctuation throughout the periods. Initially, from March 2020 to June 2020, there was an increase from approximately $52.3 billion to $63.6 billion. Afterwards, debt levels showed a general decline, reaching a low around December 2022, approximately $35.8 billion. However, starting April 2023, total debt rose sharply once again, peaking at about $71.9 billion by December 2023. Following this peak, a gradual reduction became evident towards the first quarter of 2025, with debt levels moving down to roughly $62.1 billion.
Total Capital
Total capital demonstrated a relatively steady growth trend initially, expanding from around $117.3 billion in March 2020 to approximately $164.4 billion in April 2023. Post this date, total capital remained comparatively stable with minor declines, settling near $152.4 billion by March 2025, indicating a reduction from the mid-2023 peak.
Debt to Capital Ratio
The debt to capital ratio began at 0.45 in March 2020 and rose to a peak of 0.50 in June 2020, reflecting the initial increase in debt. Subsequently, the ratio declined consistently, reaching a minimum of 0.26 around April 2023. After this low point, the ratio reversed course, climbing again to approximately 0.45 by December 2023. From then on, it displayed a slight downward movement but remained elevated relative to previous years, closing near 0.41 by March 2025.

Overall, the data indicate a period of increasing leverage early on, followed by sustained deleveraging through most of 2021 and early 2022. This was succeeded by a notable rise in leverage throughout 2023, with debt increasing faster than total capital. The modest reduction in both total debt and capital post-peak suggests efforts to rebalance the capital structure, though leverage remains higher than the levels seen in late 2021 and early 2022.


Debt to Assets

Pfizer Inc., debt to assets calculation (quarterly data)

Microsoft Excel
Mar 30, 2025 Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022 Dec 31, 2021 Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020
Selected Financial Data (US$ in millions)
Short-term borrowings, including current portion of long-term debt
Long-term debt, excluding current portion
Total debt
 
Total assets
Solvency Ratio
Debt to assets1
Benchmarks
Debt to Assets, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29).

1 Q1 2025 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =

2 Click competitor name to see calculations.


Total Debt

The total debt experienced fluctuations throughout the periods presented. Initially, total debt increased from approximately $52.3 billion in March 2020 to reach more than $63.6 billion by June 2020, before slightly decreasing and stabilizing around $39.8 billion by the end of 2020. In 2021, the debt remained relatively stable, fluctuating near $39 billion to $38 billion by December. Early 2022 showed a decrease to about $36.3 billion, followed by a moderate rise around mid-year. From late 2022 to early 2023, debt was maintained near $35.8 to $35.9 billion, but then a substantial surge occurred in the middle of 2023, reaching over $65 billion. Subsequently, total debt maintained elevated levels through late 2023 and into 2024, though showing a gradual decrease towards $62 billion by March 2025.

Total Assets

Total assets generally increased over the timeframe, with some variability. Starting near $166.3 billion in March 2020, assets rose steadily and peaked around the end of 2020 at approximately $181.5 billion, followed by a continued increase through 2021 and early 2022, reaching around $195.3 billion by mid-2022. Moving into late 2022 and early 2023, assets slightly declined but remained close to $195 billion. A notable increase occurred in early 2023, pushing assets to over $220 billion. Following this peak, assets experienced some fluctuation but stayed above $208 billion through the first quarter of 2025, indicating sustained asset base expansion over the period.

Debt to Assets Ratio

The debt to assets ratio demonstrated a declining trend from early 2020 into late 2022, indicating improved leverage and potentially reduced financial risk during that period. The ratio dropped from 0.31 in March 2020 to a low near 0.18 in late 2022, reflecting either decreasing debt levels relative to assets or increased asset base outpacing debt growth. However, starting in early 2023, the ratio increased sharply back to approximately 0.30 by mid-2023, correlating with the earlier observed debt surge and asset fluctuations. This elevated ratio was then maintained near 0.30 through the first quarter of 2025, suggesting a return to a higher leverage position compared to the trough levels observed previously.

Overall Financial Trends

The data reflects two distinct phases in the company’s financial leverage and capital structure. The initial phase, from early 2020 to late 2022, was characterized by debt reduction and asset growth, improving the debt to assets ratio. The second phase, commencing in early 2023, involved a marked increase in total debt while total assets also peaked but with a less pronounced increase, leading to a reversal in leverage trends. The sustained higher debt to asset ratios towards early 2025 highlight increased reliance on debt financing or changes in capital management strategy.

These patterns warrant further investigation into the drivers behind the sizeable debt increase in 2023 and how asset management strategies have evolved in response. Additionally, the implications for financial risk, credit metrics, and potential impacts on future funding costs should be monitored closely.


Financial Leverage

Pfizer Inc., financial leverage calculation (quarterly data)

Microsoft Excel
Mar 30, 2025 Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022 Dec 31, 2021 Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020
Selected Financial Data (US$ in millions)
Total assets
Total Pfizer Inc. shareholders’ equity
Solvency Ratio
Financial leverage1
Benchmarks
Financial Leverage, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29).

1 Q1 2025 Calculation
Financial leverage = Total assets ÷ Total Pfizer Inc. shareholders’ equity
= ÷ =

2 Click competitor name to see calculations.


The financial data over the observed periods reveals several key trends concerning the company's asset base, equity position, and financial leverage ratios.

Total Assets
The total assets show an overall fluctuating pattern across the quarters. Starting at approximately 166.3 billion US dollars in early 2020, assets increased steadily through the first three quarters of 2020, reaching a peak near 179.2 billion by the close of 2021. Following this peak, the total assets experienced a slight decline by the end of 2022, but surged again in early 2023, attaining a high of about 226.5 billion by the fourth quarter of 2023. In 2024, assets showed a declining trend, falling from approximately 221.1 billion in the first quarter to about 208 billion by the first quarter of 2025.
Total Shareholders’ Equity
The shareholders' equity also displayed variability with an overall upward trajectory through most of the timeline. Equity commenced at roughly 65 billion US dollars in early 2020, showing modest growth until the last quarter of 2020. A marked increase occurred throughout 2021 and into early 2022, peaking around 100.9 billion in early 2023. After this high, equity values declined significantly by the end of 2023 and into 2024, reaching a low near 87.2 billion in mid-2024, before a slight recovery to approximately 90.3 billion by the first quarter of 2025.
Financial Leverage
The financial leverage ratio illustrates the relationship between total assets and shareholders’ equity. The ratio decreased steadily from a high of 2.77 in mid-2020 to around 1.94 by early 2023, indicating a relative reduction in leveraged financing or an improvement in equity position relative to assets. Subsequently, this ratio rose again reaching approximately 2.54 by the fourth quarter of 2023, implying increased leverage. Throughout 2024 and into early 2025, financial leverage fluctuated mildly between 2.3 and 2.47, suggesting some stabilization in capital structure but at a higher leverage level than observed in early 2023.

Overall, the pattern indicates that the company expanded its asset base significantly through 2023 while maintaining a growing shareholders' equity until early 2023 before experiencing declines. The financial leverage trends suggest periods of deleveraging through early 2023 followed by increased leverage afterwards, reflecting dynamic adjustments in the company's financing strategy over the observed period.